Pleomorphic Xanthoastrocytoma — Variants & evidence

Pleomorphic Xanthoastrocytoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E3
Dabrafenib + TrametinibCombination	Predictive	A	Supports Sensitivity Response	1	submitted	EID11312 This study is part of an ongoing open-label, single-arm, phase 2 Rare Oncology Agnostic Research (ROAR) basket trial enlisting 45 patients (31 with glioblastoma) into the high-grade glioma cohort (oth… (full text at CIViC) PMID 34838156 · Wen et al., 2022 · Open in CIViC	civic
〃	Predictive	C	Supports Sensitivity Response	2	submitted	EID11311 In this case series, two patients with BRAF V600E mutant pleomorphic xanthoastrocytoma were treated using the BRAF inhibitor dabrafenib and trametinib in combination with the MEK inhibitor trametinib.… (full text at CIViC) PMID 28984141 · Brown et al., 2017 · Open in CIViC	civic
Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3786 An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomid… (full text at CIViC) PMID 25092772 · Lee et al., 2016 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.